Perkin-Elmer Freezes Analytical LifeSciences Market With API 3000 Debut
This article was originally published in The Gray Sheet
Perkin-Elmer's March debut of its API 3000 high-end liquid chromatography/mass spectrometry system preceded the firm's ability to commence shipping the product, effectively stalling sales of existing LC/MS systems in the final weeks of the firm's third fiscal quarter of 1998 (ended March 31).
You may also be interested in...
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.